Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
143 results about "Tumor necrosis factor receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The tumor necrosis factor receptor superfamily (TNFRSF) is a protein superfamily of cytokine receptors characterized by the ability to bind tumor necrosis factors (TNFs) via an extracellular cysteine-rich domain. With the exception of nerve growth factor (NGF), all TNFs are homologous to the archetypal TNF-alpha. In their active form, the majority of TNF receptors form trimeric complexes in the plasma membrane. Accordingly, most TNF receptors contain transmembrane domains (TMDs), although some can be cleaved into soluble forms (e.g. TNFR1), and some lack a TMD entirely (e.g. DcR3). In addition, most TNF receptors require specific adaptor protein such as TRADD, TRAF, RIP and FADD for downstream signalling. TNF receptors are primarily involved in apoptosis and inflammation, but they can also take part in other signal transduction pathways, such as proliferation, survival, and differentiation. TNF receptors are expressed in a wide variety of tissues in mammals, especially in leukocytes.
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
InactiveUS20050227935A1Improves various propertyImprove the immunitySugar derivativesGenetic material ingredientsTumor necrosis factor receptorDouble strand
This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and / or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of tumor necrosis factor and / or tumor necrosis factor receptor gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of tumor necrosis factor and / or tumor necrosis factor receptor genes, (TNF and / or TNF receptor).
Owner:SIRNA THERAPEUTICS INC
Chimeric antigen receptor
ActiveUS20140242701A1High expressionHigh cytotoxic activityAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenAntigen receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY
Immunostimulatory Combinations for Vaccine Adjuvants
This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)” or “NLR” agonists, RIG-I-Like Helicase or “RLH” agonists, purinergic receptor agonists and cytokine / chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and / or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.
Owner:RGT UNIV OF CALIFORNIA
DNA encoding tumor necrosis factor- alpha and - beta receptors
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Owner:IMMUNEX CORP
Mature dendritic cell compositions and methods for culturing same
This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-γR) agonist and / or a tumor necrosis factor alpha receptor (TNF-αR) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and / or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.
Owner:COIMMUNE INC +1
Soluble TNF receptors and their use in treatment of disease
The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
Owner:NORTH CAROLINA AT CHAPEL HILL THE UNIV OF +2
Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
InactiveUS6265535B1Improve structural stabilityInhibit bindingNGF-receptor/TNF-receptor superfamilyCyclic peptide ingredientsCyclic peptideBinding site
Owner:PENNSYLVANIA UNIV TRUSTEES OF THE
Mature dendritic cell compositions and methods for culturing same
This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-γR) agonist and / or a tumor necrosis factor alpha receptor (TNF-αR) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and / or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.
Owner:COIMMUNE INC +1
Multispecific binding molecules comprising connecting peptides
ActiveUS20090162380A1Enhance receptor signalingEnhanced signalSugar derivativesAntibody ingredientsHeavy chainBinding site
The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.
Owner:BIOGEN IDEC MA INC
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS20110201038A1Easy to adaptMicrobiological testing/measurementDisease diagnosisInterleukin 10Soluble P-Selectin
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS20120283128A1Eliminate needEasy to adaptBioreactor/fermenter combinationsBiological substance pretreatmentsMatrilysinInterleukin-1beta
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders
The invention relates to novel proteins with TNF-receptor antagonist activity and nucleic acids encoding these proteins. The invention further relates to TNF-receptor proteins with reduced immunogenicity and the use of these novel proteins in the treatment of TNF related disorders.
Owner:XENCOR INC
Chimeric antigen receptor
ActiveUS9175308B2High expressionHigh cytotoxic activityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenTumor necrosis factor receptor
Owner:MIE UNIVERSITY
Tumor necrosis factor receptor 5
InactiveUS20010021516A1Reduce capacityIncreased apoptosisBacteriaPeptide/protein ingredientsTRAIL ReceptorsAgonist
The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5," and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
Owner:HUMAN GENOME SCI INC
Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
InactiveUS20070059758A1Peptide/protein ingredientsHydrolasesTumor necrosis factor receptorNovel gene
The present invention provides compositions and methods for the regulation of cytokine signaling through the Tumor Necrosis Factor (TNF) pathway. Specifically, the invention provides a novel gene, polypeptide and related compositions and methods for the regulation of ectodomain shedding. In preferred embodiments, methods and compositions for the regulation of TNF Type-1 Receptor ectodomain shedding are provided. The present invention finds use in therapeutics, diagnostics, and drug screening applications.
Owner:THE GOVERNMENT OF THE USA OF AMERICA REP BY THE SEC DEPT OF HEALTH & HUMAN SERVICES
Methods and compositions for treating allergic reactions
InactiveUS20050059589A1BiocidePeptide/protein ingredientsTumor necrosis factor receptorAnaphylactic reaction
Methods and compositions for treating allergic reactions, including cutaneous, ocular, nasal and bronchial allergic disease, are disclosed. Interleukin-1 and Tumor Necrosis Factor receptors, and analogues thereof, are employed which bind the respective effector competitively and thereby suppress allergic reactions.
Owner:IMMUNEX CORP
Multispecific binding molecules comprising connecting peptides
ActiveUS8084026B2High binding affinityImprove localizationHybrid immunoglobulinsSugar derivativesDimerHeavy chain
Owner:BIOGEN MA INC
Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
The invention relates to, among others, a method for assessing a prognosis of a patient with a malignant disease and / or for predicting the response of a patient with a malignant disease to immunotherapy. For this purpose, a DNA methylation analysis is carried out on at least one immunoregulatory gene of cells of the malignant disease and / or T lymphocytes which interact with the cells of the malignant disease, said gene coding for an immune checkpoint selected from B7 proteins and the receptors thereof, MHC-peptide complex-binding co-receptors, the members of the tumor necrosis factor receptorsuperfamily TNFRSF9, CD40, TNFRSF4, TNFRSF18, and CD27, the members of the immunoglobulin superfamily TIGIT, BTLA, HAVCR2, BTNL2, and CD48, and the andenosine-binding adenosine 2A receptor.
Owner:迪莫迪特里希
Antibodies which specifically bind to TNF-R
Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Owner:IMMUNEX CORP
Multivalent and multispecific 41bb-binding fusion proteins
ActiveUS20170198050A1Enhanced tumor destructionInhibits inflammatory damageAntipyreticAntibody mimetics/scaffoldsBiochemistryTumor necrosis factor receptor
This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
Owner:INHIBRX INC
Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GITR or TNFRSF18)
InactiveUS20060051350A1Inhibitory responseIncrease productionOrganic active ingredientsCell receptors/surface-antigens/surface-determinantsTolerabilityGlucocorticoid
The invention relates to the field of immunology, more in particular to the field of immune therapy, even more particularly to a method for regulating tolerance to an allergen in a subject and even more specifically, to methods which involve regulation of a glucocorticoid-induced tumor necrosis factor receptor (GITR). Provided is methods of treating allergic disorder and compositions for use therein.
Owner:UTRECHT UNIVERSITY
Combination therapy for conditions leading to bone loss
InactiveUS7005413B1Increase bone densityPromoting bone accumulationPeptide/protein ingredientsAntibody mimetics/scaffoldsCombined Modality TherapyTumor necrosis factor receptor
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
Owner:AMGEN INC
Immunoactivating Antigen-Binding Molecule
ActiveUS20170022287A1Improve anti-tumor effectAvoid toxicityHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsSide effectAntigen binding
It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.
Owner:CHUGAI PHARMA CO LTD
Single domain antibodies against tnfr1 and methods of use therefor
InactiveCN101084014ALimited useReduced risk of side effects (e.g. immunosuppression)Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsSingle-domain antibodyTUMOR NECROSIS FACTOR-ALPHA RECEPTOR
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
Owner:DORMANTIS LTD
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
InactiveUS20060002935A1Reduce riskReduce usageNervous disorderVirusesTumor necrosis factor receptorTUMOR NECROSIS FACTOR-ALPHA RECEPTOR
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
Owner:DORMANTIS LTD
Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e
InactiveUS20060069246A1Improve purification effectExtended half-lifeOrganic active ingredientsFungiFusion Protein ExpressionScreening method
The invention relates to the discovery and characterization of Tango-63d, Tango-63e genes and the polypeptides they encode. Tango-63d and Tango-63e are two novel polypeptides within the tumor necrosis factor (TNF) receptor superfamily. The invention encompasses nucleic acid molecules encoding nucleic acids and polypeptides of the invention, or mutant forms thereof that encode dysfunctional receptor polypeptides, vectors containing these nucleic acid molecules, cells harboring recombinant DNA molecules encoding nucleic acids or polypeptides of the invention, or mutant forms thereof, host fusion proteins that include functional or dysfunctional polypeptides of the invention, transgenic animals that express nucleic acids or polypeptides of the invention, screening methods and therapeutic methods employing the nucleic acid molecules and polypeptides described above, substantially purified nucleic acids and polypeptides of the invention, and therapeutic compositions containing these nucleic acid molecules and polypeptides.
Owner:MILLENNIUM PHARMA INC
Combination therapy for conditions leading to bone loss
InactiveUS20050147611A1Peptide/protein ingredientsAntibody mimetics/scaffoldsCombined Modality TherapyTumor necrosis factor receptor
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
Owner:AMGEN INC
Cytokines and cytokine receptors with reduced immunogenicity
InactiveUS20050220800A1Low immunogenicityReduced immunogenic responsePeptide/protein ingredientsTissue cultureTumor necrosis factor receptorBiology
The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-β, soluble tumor necrosis factor receptor-1, erythropoietin, and thrombopoietin.
Owner:SCOTT POWER D +1
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveCN102792161AEasy to understandDisease diagnosisBiological testingBCL2 ANTAGONISTCell adhesion
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 1OB, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.
Owner:ASTUTE MEDICAL
Tumour necrosis factor receptor 1 antagonists
InactiveUS20140112929A1Preventing amplification of signal transductionEnhanced signalImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsTumor necrosis factor receptorAntagonist
Owner:GLAXO GROUP LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com